ITEM 5.02           Departure of Directors or Certain Officers; Election of Directors;
                    Appointment of Certain Officers; Compensatory Arrangements of Certain
                    Officers

Compensation for Named Executive Officers



On January 4, 2022, the Compensation Committee ("Committee") and the Board of
Directors ("Board") of Opiant Pharmaceuticals, Inc. ("Company"), and in
consultation with the Company's independent compensation consultant, Radford,
approved the following annual base
salary increases for the following named executive officers of the Company,
effective January 1, 2022:
Name                    Title                         2022 Base Salary
Dr. Roger Crystal       Chief Executive Officer       $669,445
Dr. Phil Skolnick       Chief Scientific Officer      $469,044
David O'Toole           Chief Financial Officer       $431,709

Restricted Stock Unit Grants

On January 4, 2022, the Committee and the Board approved a grant of restricted stock units ("RSU") to each of Dr. Crystal, Dr. Skolnick and Mr. O'Toole, in the amounts of 40,000 shares, 12,000 shares and 12,000 shares, respectively. Such RSU grants (i) are for common stock of the Company, (ii) vest in three equal annual amounts starting on the first anniversary of the date of grant, and (iii) were granted under the Company's 2017 Long-Term Incentive Plan ("2017 LTIP"), which was filed as Exhibit 10.52 to the Company's Annual Report on Form 10-K filed on October 13, 2017.

Target Bonus Percentage

On January 4, 2022, the Committee and the Board also approved an increase from fifty percent to sixty percent as a target bonus percentage for Dr. Crystal for the calendar year 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses